Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Metrics to compare | ANTH | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipANTHPeersSector | |
---|---|---|---|---|
P/E Ratio | 94.1x | 43.1x | −0.5x | |
PEG Ratio | 3.90 | 0.59 | 0.00 | |
Price/Book | 17.6x | 4.4x | 2.6x | |
Price / LTM Sales | 22.9x | 6.1x | 3.2x | |
Upside (Analyst Target) | - | 2.8% | 41.6% | |
Fair Value Upside | Unlock | −2.0% | 6.0% | Unlock |